Last reviewed · How we verify
NCT07327853
How Often Does the Fecal Test for Occult Blood Turn Positive After Using Blood Thinners?
trial testing Fecal Immunochemical Test (FIT) in Gastrointestinal Bleeding in 200 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Jordan Collaborating Cardiology Group |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 February 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 April 2027 |
| Sites | 1 location across Jordan |
Drugs / interventions tested
- Fecal Immunochemical Test (FIT)
Conditions studied
- Gastrointestinal Bleeding — all drugs for Gastrointestinal Bleeding →
- Antiplatelet Agents — all drugs for Antiplatelet Agents →
- Oral Anticoagulant Therapy — all drugs for Oral Anticoagulant Therapy →
Sponsor
Jordan Collaborating Cardiology Group — full company profile →
Who can join
18 and older, any sex, with Gastrointestinal Bleeding or Antiplatelet Agents. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Blood thinner medications used for cardiovascular disease can cause gastrointestinal bleeding. Early detection of invisible bleeding by performing occult fecal blood test (called fecal immunochemical test, or FIT) can uncover serious disease in the stomach and intestine and enable the treating physician to refer the patient for further evaluation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07327853
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fecal Immunochemical Test (FIT)
Trials testing the same drug.
- NCT03906110 — Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) · completed
Other recruiting trials for Gastrointestinal Bleeding
Currently open trials in the same condition.
- NCT06680583 — Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding · recruiting
Other Jordan Collaborating Cardiology Group trials
Trials by the same sponsor.
- NCT06413160 — The Cardiovascular-Renal-Metabolic (CRM) Syndrome Survey in Jordan · not yet recruiting
- NCT07275281 — Incidental Findings on Coronary Computed Tomography Angiography · not yet recruiting
- NCT07298668 — Cardiovascular Risk Factors in Middle Eastern Patients With Stroke · not yet recruiting
- NCT07039149 — Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents · recruiting
- NCT06331819 — Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and Vasovagal Symptoms. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07327853 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jordan Collaborating Cardiology Group
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07327853.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing